as 10-04-2024 4:00pm EST
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
Founded: | 2007 | Country: | United States |
Employees: | N/A | City: | BELLAIRE |
Market Cap: | 2.2M | IPO Year: | N/A |
Target Price: | $30.00 | AVG Volume (30 days): | 81.3K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -13.74 | EPS Growth: | N/A |
52 Week Low/High: | $0.86 - $21.60 | Next Earning Date: | 11-13-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
BPTH Breaking Stock News: Dive into BPTH Ticker-Specific Updates for Smart Investing
GlobeNewswire
20 days ago
Newsfile
a month ago
GlobeNewswire
a month ago
MT Newswires
a month ago
GlobeNewswire
a month ago
Associated Press Finance
2 months ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
The information presented on this page, "BPTH Bio-Path Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.